Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

General Information

Offices

M.P. Misgav, ISR
Misgav Business Park
M.P. Misgav, 20174, ISR

Funding

VENTURE FUNDING
Venture Round, 5/2013
SCRA

Tags

NeuroQuest

Neurodegenerative diseases remain unpreventable, incurable, and largely untreatable. Today, diagnosis is typically carried out through psychiatric examination at advanced stages of the disease when the damage is significant and the potential for delaying disease progression is low.

There is an urgent need for rapid, low-cost, accurate diagnostic tests for Alzheimer’s disease (AD) and ALS (Lou Gehrig’s disease) early in their course when therapy is most effective and permits better disease management.

One in eight people over the age of 65 have AD, with over 5.1 million patients in the U.S. Incorporating an accurate diagnostic capable of monitoring disease progression will greatly ease the burden of late-stage diagnosis on families — and the health system. The U.S. Surgeon General and the UK’s NHS recognize this milestone as a top priority in the treatment of Alzheimer’s

Recent Milestones

Videos

Screenshots

NeuroQuest screenshot
Above: NeuroQuest
Uploaded: 5/14/13

Sources

  1. NeuroQuest Receives Investment from SCRA Technology Ventures (finsmes.com) [edit]
Edit This Page
Last Edited 12/4/13

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy